Assuntos
Formulários Farmacêuticos como Assunto/normas , Seguro de Serviços Farmacêuticos/legislação & jurisprudência , Medicaid/legislação & jurisprudência , Planos Governamentais de Saúde/economia , Controle de Custos , Estudos de Avaliação como Assunto , Gastos em Saúde , Acessibilidade aos Serviços de Saúde/economia , Acessibilidade aos Serviços de Saúde/legislação & jurisprudência , Acessibilidade aos Serviços de Saúde/normas , Humanos , Medicaid/economia , Mecanismo de Reembolso/legislação & jurisprudência , Estados UnidosRESUMO
This study expands our previous work on the availability of new drug introductions to poor patients in states in the USA with restrictive Medicaid formularies. In particular, it focuses on the experience of 9 states over the period 1979 to 1985. In these states, a typical new drug took 20 months after FDA approval to gain acceptance onto the Medicaid formulary. New drug introductions were available to Medicaid patients less than 40% of the time during their first 4 years of market life. Restrictions on availability also extended to drugs ranked high in terms of both therapeutic and commercial importance. There was substantial variation observed across states and therapeutic categories. While formularies are prohibited under legislation recently enacted by the US Congress, state governments may attempt to continue to restrict access to expensive new medicines through prior approval systems. This is an issue that warrants future attention and study.
